Sept 21 (Reuters) - Versartis Inc
* Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint
* Versartis Inc - Study did not meet its primary endpoint of non-inferiority.
* Versartis Inc says somavaratan was well tolerated with treatment discontinuation rate lower than for genotropin arm.
* Versartis Inc - No new emergent safety signals were observed in the study Source text for Eikon: Further company coverage: